Lyra Therapeutics to Present 52-week Extension Stage Results for ENLIGHTEN 1 Phase 3 Study for LYR-210 for the Treatment of Chronic Rhinosinusitis at COSM 2025
Provided By GlobeNewswire
Last update: May 7, 2025
WATERTOWN, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting, anti-inflammatory sinonasal implants for the treatment of chronic rhinosinusitis (CRS), today announced that the Company plans to present results from the 52-week Extension Stage of the ENLIGHTEN 1 Phase 3 study for LYR-210, the Company’s lead product candidate for CRS, at the annual Combined Otolaryngology Spring Meetings (COSM 2025) being held May 14-18 in New Orleans.
Read more at globenewswire.com11.85
-1.65 (-12.22%)
Find more stocks in the Stock Screener
LYRA Latest News and Analysis
4 days ago - ChartmillLet's have a look at the top gainers and losers in the middle of the day of today's session.Let's have a look at what is happening on the US markets in the middle of the day on Monday. Below you can find the top gainers and losers in today's session.
10 days ago - ChartmillWhat's going on in today's sessionStay up-to-date with the latest market trends one hour before the close of the markets on Tuesday. Explore the top gainers and losers during today's session in our detailed report.
10 days ago - ChartmillWhich stocks are moving on Tuesday?Curious about what's happening in today's session? Check out the latest stock movements and price changes.
